Anaptys Biosciences is a venture-backed biopharmaceutical company focused on the rapid discovery and development of novel monoclonal antibodies and therapeutic proteins. We use a proprietary technology based on somatic cell hypermutation, a natural process of mutagenesis, which enables the rapid variation and functional selection of evolved proteins with enhanced bioactivities.
